Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 9, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-26-004890
Filed / recorded
Feb 12, 2026, 2:00 AM UTC
Added to OQRO
Oct 6, 2026, 9:54 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ADMA BIOLOGICS, INC.
Issuer CIK
1368514
Ticker
ADMA
Reporting person
Adam S Grossman
Relationship
Director, Officer
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 9, 2026
Transaction code
A
Shares / units
282,529
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
2,290,379
Ownership form
Direct
Amendment
No
Footnotes from the filing
These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.
Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.